Shanxi C&Y Pharmaceutical Group (300254.SZ) released its performance for the first three quarters, with a net income of 44.1533 million yuan.

Zhitong Finance · Oct 23 17:38

Shanxi C&Y Pharmaceutical Group (300254.SZ) released the third quarter report for 2024, with the company's revenue for the first three quarters totaling 6...

Zhifinance APP news, Shanxi C&Y Pharmaceutical Group (300254.SZ) released the third quarter report for 2024, with the company's revenue for the first three quarters totaling 0.609 billion yuan, a year-on-year increase of 6.45%. The net income attributable to shareholders of the listed company was 44.1533 million yuan. The net income attributable to shareholders of the listed company after deducting non-recurring gains and losses was 27.2708 million yuan. The basic earnings per share was 0.1827 yuan.

The translation is provided by third-party software.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.

仟源医药(300254.SZ)发布前三季度业绩，净利润4415.33万元

Shanxi C&Y Pharmaceutical Group (300254.SZ) released its performance for the first three quarters, with a net income of 44.1533 million yuan.

Risk Disclaimer

Statement